A new device improves behaviours in autistic children without drugs – and stocks in the tech company behind it are skyrocketing – Business Insider

Shares in Neurotech International surged after announcing the results of a US trial for the company’s at-home device for children with autism.

The shares surged up to 30% higher but at the close they were down 3.2% to $0.15.

Neurotech says the full results of the US clinical trial for its Mente Autism device, published by leading medical journal Frontiers in Neurology, showed a reduction in autistic behaviours as well as improved social and communication skills.

The study, administered by Carrick Institute, was a double-blind investigation of 34 subjects over 12 weeks. Those with autism find it difficult to communicate with and form relationships with other people.

“When we first designed the study, Mente Autism was of interest as it is a novel tool that takes clinical neurofeedback, an established non-invasive biofeedback approach for the treatment of autism, and makes this really accessible as a treatment option for parents of children with autism,” says Professor Frederick Carrick, lead author of the publication.

“As we flagged along the way, we have been very excited that the study has yielded statistically significant results which show improvements across a wide range of functional areas in the Active group, and not in the Control group.

Read more at: http://uk.businessinsider.com/a-new-drug-free-device-has-been-shown-to-improve-autistic-behaviours-2018-7

Font Resize